never underestimate the tenacity of ashorts with large positions. They will continue to cover incrementally, and slowly, using a bunch of techniques, as long as it takes, Look at ARNA as a good example, check out the short interest steadily decline while the SP remains relatively flat. Even after buy out announcements, they will continue to manipulate. Long terms hold is the play...
borrowing more shares to dump and bottom feeding on stops has really worked well for the shorts. lol must be some year end disparate move. Why sell at this point? Shorts cannot apply their models to any BT and expect to come out ahead all the time. Hold Strong.
based upon the financing decision to direct the proceeds to go with plecantide alone, i would guess that no development partner is in the works and SGYP will either promote it themselves with their own newly hired or contract sales force, or they will sell the molecule and receive a royalty, or go for a buy out. If anyone sees a headhunter ad for a VP of sales and reps then we know which way they will go post FDA approval. shorts will dump on any news, but are screwed.
my issue is the holders that decide to flip the 3.11 warrants and take immediate gains may help the shorts cover
"Company may not redeem the Notes prior to the Maturity Date. Holders may surrender their Notes for conversion at any time prior to the close of business on the business day immediately preceding the Maturity Date. The initial conversion rate will be 321.5434 shares of the Company's Common Stock for each $1,000 principal amount of Notes, which represents an initial conversion price of approximately $3.11 per share. The conversion rate is subject to adjustment under certain circumstances described in the Indenture."